duchenn
muscular
dystrophi
dmd
fatal
xlink
muscl
wast
disord
childhood
caus
mutat
dystrophin
gene
dmd
commonli
frameshift
delet
one
exon
review
emeri
milder
allel
condit
becker
muscular
dystrophi
bmd
also
caus
dystrophin
mutat
typic
infram
delet
allow
synthesi
intern
truncat
dystrophin
isoform
retain
partial
function
character
dystrophin
gene
arrang
mildli
affect
asymptomat
bmd
individu
reveal
delet
substanti
domain
dmd
gene
yield
dystrophin
isoform
nearnorm
function
observ
led
concept
target
exon
remov
around
dmd
mutat
refram
dystrophin
transcript
supposit
strategi
could
treat
dmd
spliceswitch
antisens
oligom
first
use
dominski
kole
modifi
splice
transcript
subsequ
shown
induc
dystrophin
exon
skip
read
frame
disrupt
takeshima
et
al
proof
concept
target
exon
remov
could
restor
dystrophin
express
vivo
demonstr
mdx
mice
mann
et
al
dog
model
dmd
yokota
et
al
recent
dmd
patient
van
deutekom
et
al
kinali
et
al
cirak
et
al
goeman
et
al
oligom
design
clinic
studi
focus
remov
exon
flank
frameshift
delet
two
dystrophin
delet
hotspot
howev
numer
motif
control
exon
select
splice
mutat
ablat
gene
express
caus
diseas
splice
motif
disrupt
prevent
proper
exon
select
result
use
cryptic
splice
site
caus
partial
exon
loss
intron
retent
may
gener
multipl
aberr
transcript
fernandezcadena
et
al
deep
intron
mutat
activ
pseudoexon
inclus
matur
gene
transcript
although
pseudoexon
activ
dystrophin
gene
transcript
rare
event
type
gene
lesion
target
exon
skip
would
lead
normal
fulllength
gene
transcript
gurvich
colleagu
report
two
dmd
case
caus
inclus
pseudoexon
deriv
intron
subsequ
oligomerinduc
skip
aberr
exon
gurvich
et
al
dystrophin
splice
site
mutat
rel
neglect
target
dmd
therapeut
exon
skip
studi
despit
report
splice
motif
chang
caus
least
mutat
human
inherit
diseas
krawczak
et
al
earli
studi
dmdbmd
case
robert
et
al
correct
exon
select
requir
basic
cisact
element
import
exon
recognit
canon
splice
site
embed
within
context
noncanon
sequenc
conduc
splice
site
recognit
bind
splice
factor
krawczak
et
al
mutat
canon
noncanon
sequenc
weaken
splice
site
recognit
may
result
exon
skip
consequ
difficult
predict
de
conti
et
al
donor
splice
site
definit
key
step
splice
site
recognit
mutat
affect
junction
report
result
exon
skip
immedi
vicin
devoid
altern
splice
site
krawczak
et
al
report
use
spliceswitch
antisens
oligom
ao
bypass
two
donor
splice
site
mutat
one
involv
exon
impact
upon
exon
process
inactiv
donor
splice
site
lead
exon
skip
may
expect
krawczak
et
al
instead
caus
retent
downstream
intron
despit
similar
one
mutat
respond
singl
exon
skip
requir
dual
exon
skip
overcom
diseasecaus
mutat
restor
open
read
frame
found
small
dystrophin
gene
lesion
appear
variou
dystrophin
splice
site
mutat
requir
person
oligom
design
exon
skip
strategi
casebycas
basi
forrest
et
al
fragal
et
al
adkin
et
al
modifi
base
phosphorothio
backbon
synthes
expedit
synthes
appli
biosystem
melbourn
australia
describ
previous
adam
et
al
ao
nomenclatur
base
upon
target
exon
number
oligom
anneal
coordin
describ
mann
et
al
oligom
amen
site
prepar
suppli
sarepta
therapeut
bothel
wa
phosphorodiamid
morpholino
oligom
conjug
cell
penetr
peptid
ppmok
rxr
b
r
larginin
x
acid
moulton
et
al
jearawiriyapaisarn
et
al
moulton
moulton
detail
design
optim
oligom
sequenc
target
exon
remov
report
previous
hard
et
al
exon
oligom
sequenc
shown
tabl
normal
patient
biopsi
sampl
collect
inform
consent
deidentifi
use
human
tissu
studi
approv
univers
western
australia
human
ethic
committe
approv
number
fibroblast
myogen
cell
normal
dmd
patient
muscl
biopsi
expand
differenti
describ
previous
adkin
et
al
cell
patient
carri
exon
donor
splice
site
obtain
muscl
biopsi
dermal
fibroblast
prepar
skin
biopsi
dmd
patient
exon
splice
site
mutat
normal
myogen
cell
extract
surplu
muscl
biopsi
fragment
patient
undergo
elect
procedur
inform
consent
fibroblast
convert
myoblast
forc
myogenesi
lattanzi
et
al
transduct
myod
express
adenoviru
nativ
antigen
compani
oxford
uk
differenti
low
serum
media
briefli
patient
fibroblast
cultur
confluent
wash
phosphat
buffer
salin
pb
detach
trypsin
wv
gibco
life
technolog
inactiv
medium
contain
fc
pellet
centrifug
g
resuspend
dmem
life
technolog
supplement
hors
serum
ad
multipl
infect
cell
seed
cell
per
well
well
plate
sequenti
pretreat
h
poli
dlysin
sigma
melbourn
australia
matrigel
bd
bioscienc
north
ryde
australia
twentyfour
hour
later
medium
replac
cell
allow
differenti
h
forc
myogenesi
transfect
oligom
experi
forc
myogenesi
fibroblast
adequ
rna
studi
alway
effici
enough
result
induc
dystrophin
level
detect
western
blot
depend
qualiti
origin
cell
prepar
ao
transfect
cation
lipoplex
lipofectamin
ww
life
technolog
melbourn
australia
optimem
media
gibco
life
technolog
per
manufactur
instruct
hard
et
al
ppmok
transfect
cell
concentr
indic
describ
adkin
et
al
incub
specifi
rna
extract
rtpcr
undertaken
use
ng
total
rna
templat
primari
amplif
use
iii
onestep
rtpcr
system
platinum
taq
life
technolog
amplifi
across
specifi
dystrophin
exon
cycl
myoblast
cycl
myod
convert
fibroblast
aliquot
remov
subject
nest
pcr
cycl
use
amplitaq
gold
appli
biosystem
melbourn
australia
detail
pcr
primer
genework
adelaid
australia
shown
tabl
amplicon
fraction
agaros
gel
tae
buffer
rel
exon
skip
effici
estim
densitometri
fulllength
oligomerinduc
pcr
product
imag
captur
chemismart
system
vilber
lourmat
franc
adam
et
al
ident
induc
transcript
confirm
direct
dna
sequenc
undertaken
australian
genom
research
facil
perth
australia
densitometr
analysi
use
softwar
scientif
softwar
group
provo
ut
cell
transfect
oligom
sequenc
target
exon
acceptor
splice
site
prepar
ppmok
ao
cation
lipoplex
nmoll
incub
day
harvest
western
blot
analysi
mcclorey
et
al
protein
extract
normal
cell
oligom
treat
untreat
load
onto
denatur
gradient
polyacrylamid
gel
electrophoresi
western
blot
perform
use
novocastra
laboratori
newcastleupontyn
uk
protocol
deriv
cooper
et
al
nicholson
et
al
describ
detail
previous
fletcher
et
al
protein
load
standard
accord
myosin
heavi
chain
express
assess
densitometri
coomassi
blue
stain
gradient
gel
fletcher
et
al
imag
captur
vilber
lourmat
chemismart
system
use
chemicapt
softwar
imag
acquisit
softwar
imag
analysi
failur
gener
consist
rtpcr
product
across
exon
rna
extract
untreat
cell
suggest
dystrophin
transcript
either
absent
present
extrem
low
level
howev
amplif
across
exon
confirm
dystrophin
mrna
inde
present
could
readili
detect
standard
amplif
condit
fig
b
rtpcr
carri
use
primer
combin
ascertain
intron
retain
within
matur
mrna
forward
primer
direct
exon
revers
primer
target
intron
well
forward
primer
anneal
near
end
intron
revers
primer
target
exon
use
rtpcr
product
gener
patient
rna
correspond
amplicon
expect
length
intron
retain
remaind
transcript
correctli
splice
fig
signal
gener
rna
extract
normal
human
muscl
dna
sequenc
exon
product
show
dystrophin
exon
correctli
splice
exon
begin
intron
retain
transcript
data
shown
similarli
exon
correctli
splice
end
intron
includ
patient
transcript
lead
us
conclud
kb
intron
retain
splice
expect
result
fulllength
muscl
specif
dystrophin
transcript
estim
excess
kb
kb
intron
retain
within
kb
normal
size
mrna
transfect
cell
patient
antisens
oligom
target
exon
acceptor
splice
site
rna
extract
amplifi
nest
rtpcr
shown
figur
dystrophin
transcript
miss
exon
readili
detect
lowest
transfect
concentr
amplicon
nearnorm
length
detect
rna
extract
untreat
cell
fig
ut
lane
gener
sporad
fig
previous
identifi
arisen
activ
cryptic
exon
donor
splice
site
mitrpant
et
al
aberr
splice
site
one
base
upstream
correct
splice
site
calcul
donor
splice
site
score
shorter
amplicon
appar
untreat
sampl
cell
transfect
nmoll
previous
report
arisen
spontan
skip
exon
mitrpant
et
al
dystrophin
express
studi
undertaken
myogen
cell
transfect
prepar
modifi
base
phosphorothio
backbon
phosphorodiamid
morpholino
oligom
coupl
cell
penetr
peptid
ppmok
nearnorm
level
dystrophin
express
detect
ppmok
treat
patient
cell
wherea
treat
result
undetect
dystrophin
express
condit
fig
consist
previou
experi
dystrophin
could
induc
readili
detect
level
myogen
cell
transfect
fletcher
et
al
mcclorey
et
al
absenc
dystrophin
untreat
patient
sampl
would
indic
infram
revert
fiber
transcript
miss
exon
present
level
low
gener
detect
dystrophin
rtpcr
across
region
dystrophin
transcript
remot
exon
gene
lesion
indic
matur
dystrophin
mrna
present
cell
fig
b
failur
reproduc
gener
rtpcr
amplicon
across
exon
suggest
retent
intron
confirm
rtpcr
use
forward
primer
target
exon
revers
primer
anneal
within
intron
forward
primer
anneal
end
intron
revers
primer
target
exon
fig
dna
sequenc
confirm
junction
data
shown
assum
intron
retain
entireti
would
result
kb
dystrophin
transcript
consequ
exon
donor
splice
site
mutat
excis
exon
alon
disrupt
dystrophin
read
frame
henc
necessari
excis
either
exon
exon
matur
mrna
allow
translat
bmdlike
dystrophin
isoform
singl
dual
oligom
prepar
target
exon
transfect
normal
myogen
cell
dosedepend
induct
exon
skip
shown
figur
dual
exon
skip
exon
appear
similarli
effici
perhap
cocktail
target
exon
margin
effect
demonstr
lower
amount
fulllength
dystrophin
transcript
amplicon
fig
e
oligom
target
exon
respect
transfect
patient
cell
individu
combin
singl
exon
excis
gener
detect
transcript
patient
cell
fig
apart
applic
transfect
concentr
nmoll
amplicon
expect
size
miss
exon
observ
fig
inabl
amplifi
product
rna
appear
due
retent
intron
patient
dystrophin
mrna
result
transcript
target
size
would
preclud
rtpcr
amplif
oligom
combin
target
exon
exon
transfect
patient
cell
induc
abund
transcript
product
miss
target
exon
combin
exon
exclus
effici
induc
concentr
nmoll
exon
skip
appear
less
effect
reflect
amount
induc
transcript
presenc
intermedi
product
cell
transfect
nmoll
less
fig
j
rtpcr
detect
dystrophin
transcript
retain
intron
confirm
failur
gener
signal
result
singl
exon
skip
due
retent
intron
sequenc
howev
transfect
concentr
nmoll
skip
exon
complet
suppress
intron
retent
fig
although
transfect
patient
cell
ao
target
exon
induc
robust
exon
skip
intron
specif
rtpcr
indic
presenc
transcript
retain
intron
concentr
data
shown
forc
myogenesi
dermal
fibroblast
induc
suffici
dystrophin
express
permit
rna
studi
cell
qualiti
permit
protein
analysi
western
blot
howev
case
myogen
capac
myod
transduc
patient
cell
adequ
dystrophin
detect
data
shown
antisens
oligomermedi
exon
skip
refram
dystrophin
gene
transcript
show
great
promis
potenti
therapi
overcom
dmdcaus
mutat
dystrophin
express
report
system
administr
spliceswitch
oligom
two
differ
chemistri
dmd
patient
cirak
et
al
goeman
et
al
howev
unlik
gene
cell
replac
approach
one
treatment
applic
dmd
patient
regardless
primari
gene
lesion
target
exon
skip
strategi
must
tailor
mutat
may
person
individu
first
requir
accur
genet
diagnosi
precis
identif
gene
lesion
dna
prefer
gene
transcript
level
mutat
analysi
dna
level
reliabl
identifi
gross
genet
lesion
prematur
termin
codon
caus
genet
diseas
howev
sever
mechan
alter
disrupt
gene
express
includ
alter
affect
fidel
premrna
splice
review
see
baral
et
al
consequ
small
insert
delet
point
mutat
process
dystrophin
gene
transcript
difficult
predict
therefor
clinic
implic
dna
chang
best
determin
transcript
analysi
although
complic
necess
rna
sampl
prepar
appropri
tissu
disrupt
canon
splice
site
would
expect
disrupt
splice
howev
effect
mutat
noncanon
base
branch
point
splice
regulatori
element
modul
ci
tran
act
factor
rna
secondari
structur
earli
estim
suggest
human
point
mutat
result
aberr
splice
krawczak
et
al
although
recogn
underestim
gene
baral
et
al
jensen
et
al
import
aberr
splice
caus
human
diseas
lead
advanc
tool
predict
consequ
particular
nucleotid
variat
gene
express
de
conti
et
al
uncertainti
model
complex
system
limit
accuraci
predict
baral
et
al
common
consequ
mutat
affect
authent
splice
site
skip
one
exon
follow
aberr
donor
acceptor
splice
activ
baral
baral
buratti
et
al
retent
entir
intron
less
commonli
report
major
diseasecaus
point
mutat
affect
splice
occur
donor
site
krawczak
et
al
result
metaanalysi
diseaseassoci
splice
mutat
consist
correct
donor
splice
site
recognit
key
step
exon
recognit
pathogen
missens
chang
human
gene
like
affect
mrna
splice
krawczak
et
al
splice
site
mutat
dmd
gene
report
result
either
dmd
bmd
intermedi
phenotyp
human
sironi
et
al
adachi
et
al
thi
tran
et
al
takeshima
et
al
magri
et
al
dmdlike
diseas
natur
occur
golden
retriev
grmd
canin
model
dmd
aris
singl
base
chang
affect
dystrophin
exon
acceptor
splice
site
sharp
et
al
result
omiss
exon
matur
dystrophin
transcript
disrupt
read
frame
restor
exclus
exon
demonstr
vitro
mcclorey
et
al
vivo
yokota
et
al
first
examin
dystrophin
transcript
cell
dmd
patient
rtpcr
across
gene
lesion
fail
yield
reproduc
amplicon
result
inconsist
skip
respect
exon
consid
unlik
nonsensemedi
decay
alon
could
account
appear
extrem
low
level
transcript
routin
detect
dystrophin
transcript
mani
differ
dmd
patient
cell
tissu
sampl
equival
amplif
condit
arechavalagomeza
et
al
forrest
et
al
fragal
et
al
adkin
et
al
henc
hypothes
catastroph
disrupt
premrna
process
may
ablat
dystrophin
transcript
downstream
gene
lesion
howev
amplif
dystrophin
mrna
upstream
downstream
defect
indic
transcript
inde
present
case
inabl
gener
product
across
mutat
limit
rtpcr
undertak
rtpcr
forward
primer
direct
exon
revers
primer
anneal
within
intron
gener
amplif
product
expect
size
rna
intron
retain
within
matur
transcript
amplicon
could
arisen
dna
contamin
intron
base
kb
respect
would
preclud
amplif
condit
similar
experi
use
forward
primer
anneal
toward
end
intron
revers
primer
target
exon
also
gener
product
anticip
size
intron
retain
within
matur
mrna
shorter
expect
amplicon
detect
rna
extract
untreat
oligomertr
cell
report
previous
mitrpant
et
al
smaller
product
detect
frequent
studi
identifi
dna
sequenc
presum
arisen
endogen
skip
exon
amplicon
also
detect
untreat
cell
typic
revert
fiber
transcript
report
present
least
dmd
patient
sherratt
et
al
winnard
et
al
particular
transcript
infram
occur
low
frequenc
demonstr
sporad
detect
rna
level
absenc
dystrophin
western
blot
parallel
rtpcr
studi
confirm
end
intron
present
dystrophin
mrna
express
cell
primer
walk
indic
least
first
last
kb
intron
retain
northern
blot
could
confirm
retent
entir
intron
matur
mrna
consid
necessari
intern
cleavag
render
transcript
suscept
degrad
davidson
et
al
furthermor
inabl
reproduc
gener
amplicon
across
mutat
studi
consist
retent
substanti
portion
intron
consequ
kb
matur
dystrophin
mrna
would
increas
length
fold
exon
splice
mutat
respect
transfect
exon
target
oligom
patient
cell
concentr
nmoll
induc
transcript
miss
exon
intron
readili
detect
manner
appear
dose
depend
transfect
concentr
nmoll
amplicon
pattern
sporad
similar
observ
untreat
cell
thu
assum
indic
lack
rescu
transcript
subsequ
titrat
show
exon
skip
could
induc
patient
cell
transfect
lower
concentr
nmoll
amplicon
repres
dystrophin
transcript
miss
exon
sporad
data
shown
consist
retent
intron
major
transcript
suggest
possibl
threshold
effect
effici
splice
switch
mutat
interestingli
first
report
exon
skip
normal
human
myogen
cell
oligom
transfect
rang
nmoll
hard
et
al
dose
respons
appar
subsequ
titrat
oligom
normal
human
myogen
cell
show
clear
dose
respons
nmoll
data
shown
observ
patient
cell
inabl
reliabl
induc
exon
excis
patient
cell
low
oligom
concentr
could
reflect
influenc
donor
splice
site
mutat
oligomerinduc
modif
dystrophin
splice
patient
unexpect
previous
show
small
dmd
mutat
influenc
oligomermedi
exon
skip
outcom
forrest
et
al
fragal
et
al
mutat
affect
dystrophin
exon
commonli
encount
exon
would
consid
low
prioriti
therapeut
target
except
patient
famili
despit
rare
perhap
uniqu
natur
mutat
report
patient
could
consid
excel
candid
person
exon
skip
target
exon
excis
high
effici
least
vitro
significantli
loss
exon
appear
compromis
dystrophin
function
schwartz
et
al
chanc
sever
member
famili
identifi
miss
exon
asymptomat
individu
show
elev
serum
creatin
kinas
level
intent
appli
exon
skip
dystrophin
transcript
convert
dmd
premrna
bmdlike
isoform
howev
loss
exon
matur
dystrophin
gene
transcript
result
dystrophin
normal
function
conceiv
induct
low
level
normal
dystrophin
would
confer
substanti
therapeut
benefit
therefor
patient
may
better
candid
clinic
evalu
whose
common
mutat
allow
gener
somewhat
compromis
bmdlike
dystrophin
isoform
unlik
exon
exon
within
high
prioriti
dystrophin
target
region
induc
exon
skip
exclus
exon
potenti
applic
estim
dmd
case
van
deutekom
van
ommen
aartsmaru
et
al
howev
skip
exon
alon
benefit
dystrophin
transcript
miss
exon
outoffram
dual
skip
either
exon
requir
read
frame
rescu
spliceswitch
oligom
previous
design
optim
excis
exon
transfect
normal
myogen
cell
either
individu
combin
induc
robust
dosedepend
exon
skip
oligom
target
exon
detect
spliceswitch
effect
patient
cell
experi
suggest
intron
retain
dystrophin
mrna
preclud
amplicon
gener
subsequ
confirm
nest
rtpcr
carri
exon
intron
spliceswitch
ao
induc
robust
exon
skip
normal
cell
nmoll
decreas
effici
evid
lower
concentr
oligom
transfect
patient
cell
pronounc
threshold
effect
oligom
concentr
nmoll
higher
necessari
excis
exon
suppress
intron
retent
dmd
transcript
vitro
dual
exon
target
effici
exclud
exon
exon
patient
cell
readili
detect
dystrophin
amplicon
expect
size
transfect
concentr
nmoll
nmoll
oligom
higher
exon
skip
appear
effect
strategi
determin
rel
amount
induc
amplicon
reflect
dual
exon
skip
transfect
patient
cell
either
oligom
cocktail
nmoll
induc
detect
product
suggest
retent
intron
skip
exon
appear
less
effect
specif
rtpcr
assay
confirm
presenc
transcript
retain
intron
surprisingli
intron
specif
rtpcr
assay
indic
transcript
retain
intron
despit
seemingli
effici
exon
skip
probabl
natur
donor
splice
site
mutat
togeth
size
flank
intron
impact
upon
oligomerinduc
exon
skip
overcom
exon
gene
lesion
readili
achiev
skip
singl
exon
flank
intron
total
expans
kb
contrast
address
exon
splice
mutat
necessit
remov
two
exon
associ
intron
intron
longest
dmd
perhap
gene
kb
length
skip
exon
requir
kb
premrna
excis
wherea
altern
strategi
remov
exon
exclud
kb
primari
gene
transcript
two
possibl
could
account
variabl
dual
exon
skip
effici
oligom
excis
target
exon
equal
effici
exon
skip
normal
cell
less
effect
remov
exon
although
complic
use
oligom
combin
assess
normal
myogen
cell
excis
exon
appear
effici
skip
exon
anoth
consider
possibl
upper
limit
distanc
exon
permit
lariat
format
subsequ
splice
summari
describ
two
dmd
donor
splice
site
mutat
unexpectedli
led
retent
entir
downstream
intron
transcript
difficulti
mrna
character
rtpcr
primer
anneal
intron
use
despit
superfici
similar
gene
transcript
respond
singl
exon
skip
nearnorm
level
dystrophin
restor
vitro
assess
western
blot
contrast
dystrophin
transcript
amen
singl
exon
skip
wherea
dual
skip
exon
effici
induc
clear
threshold
effect
evid
suggest
like
exon
skip
strategi
need
individu
mani
nondelet
dmd
case
